Disc Medicine, Inc. financial data

Symbol
IRON on Nasdaq
Industry
Pharmaceutical Preparations
Location
321 Arsenal Street, Suite 101, Watertown, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Gemini Therapeutics, Inc. /DE (to 12/28/2022), FS Development Corp. (to 2/8/2021)
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.44 K % +49.9%
Debt-to-equity 4.91 % -73.6%
Return On Equity -22.8 % +78.2%
Return On Assets -21.7 % +39.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 24.7 M shares +29.9%
Common Stock, Shares, Outstanding 24.7 M shares +26.2%
Entity Public Float 508 M USD +1651%
Common Stock, Value, Issued 2 K USD 0%
Weighted Average Number of Shares Outstanding, Basic 24.8 M shares +30.9%
Weighted Average Number of Shares Outstanding, Diluted 24.8 M shares +30.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 72.8 M USD +58.9%
General and Administrative Expense 24.7 M USD +46.5%
Operating Income (Loss) -97.5 M USD -55.6%
Nonoperating Income (Expense) 16.9 M USD +483%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -80.5 M USD -34.8%
Income Tax Expense (Benefit) 81 K USD -78.3%
Net Income (Loss) Attributable to Parent -80.6 M USD -34.9%
Earnings Per Share, Basic -3.31 USD/shares +90.7%
Earnings Per Share, Diluted -3.31 USD/shares +90.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 343 M USD +44.9%
Assets, Current 352 M USD +45.4%
Property, Plant and Equipment, Net 211 K USD +17.2%
Operating Lease, Right-of-Use Asset 1.79 M USD +32.8%
Other Assets, Noncurrent 235 K USD +103%
Assets 354 M USD +45.3%
Accounts Payable, Current 5.27 M USD -6.61%
Employee-related Liabilities, Current 2.16 M USD +146%
Accrued Liabilities, Current 8.82 M USD +119%
Liabilities, Current 14.9 M USD +48.8%
Operating Lease, Liability, Noncurrent 1.26 M USD +33.2%
Liabilities 16.1 M USD +47.5%
Retained Earnings (Accumulated Deficit) -216 M USD -59.7%
Stockholders' Equity Attributable to Parent 338 M USD +45.2%
Liabilities and Equity 354 M USD +45.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -33.6 M USD +5.26%
Net Cash Provided by (Used in) Financing Activities 15.9 M USD -79.4%
Net Cash Provided by (Used in) Investing Activities -67 K USD -131%
Common Stock, Shares Authorized 100 M shares 0%
Common Stock, Shares, Issued 24.7 M shares +26.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -17.8 M USD -142%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 343 M USD +44.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 47 K USD -21.7%
Deferred Tax Assets, Valuation Allowance 61.8 M USD +71.1%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 62.3 M USD +70.6%
Operating Lease, Liability 2.1 M USD +57.5%
Depreciation 0 USD -100%
Payments to Acquire Property, Plant, and Equipment 67 K USD +131%
Lessee, Operating Lease, Liability, to be Paid 2.42 M USD +63.2%
Operating Lease, Liability, Current 767 K USD +145%
Lessee, Operating Lease, Liability, to be Paid, Year Two 850 K USD +123%
Lessee, Operating Lease, Liability, to be Paid, Year One 845 K USD +127%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +90.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 323 K USD +114%
Lessee, Operating Lease, Liability, to be Paid, Year Three 729 K USD +85%
Deferred Tax Assets, Operating Loss Carryforwards 24.3 M USD +28.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 336 K USD
Operating Lease, Payments 186 K USD -61.3%
Additional Paid in Capital 554 M USD +50.5%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 26 K USD +4%
Deferred Tax Assets, Net of Valuation Allowance 555 K USD +32.1%
Share-based Payment Arrangement, Expense 8.56 M USD +208%
Interest Expense 240 K USD -96.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%